Abbott Laboratories' Q3 comparable sales growth market reflects trader focus on the company's reaffirmed full-year 2026 guidance of 6.5% to 7.5% organic growth, which incorporates the Exact Sciences acquisition and anticipates second-half acceleration. Q2 2026 delivered 4.8% comparable growth amid 13% reported revenue expansion, supported by medical devices momentum in electrophysiology and diabetes care plus easing China diagnostics headwinds. Analysts project Q3 revenue near $13 billion, with segment contributions from nutrition recovery and cancer diagnostics integration driving the 6% to 8% range to a 69.5% implied probability. Earnings release on October 21 will clarify whether momentum sustains against foreign exchange and competitive pressures.